Relevant bibliographies by topics / Cancer ablation

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Cancer ablation'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cancer ablation.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cancer ablation"

1

Sweeney, Jennifer, Nainesh Parikh, Ghassan El-Haddad, and Bela Kis. "Ablation of Intrahepatic Cholangiocarcinoma." Seminars in Interventional Radiology 36, no. 04 (October 2019): 298–302. http://dx.doi.org/10.1055/s-0039-1696649.

Full text
Abstract:
AbstractIntrahepatic cholangiocarcinoma is the second most common primary liver cancer but represents only a small portion of all primary liver cancers. At the time of diagnosis, patients are often not surgical candidates due to tumor burden of other comorbidities. In addition, there is a very high rate of tumor recurrence after resection. Local regional therapies, specifically ablative therapies of radiofrequency ablation, microwave ablation, cryoablation, and irreversible electroporation, have proven to be beneficial with other hepatic tumors. The purpose of this review is to provide an overview and update of the medical literature demonstrating ablative therapy as a treatment option for intrahepatic cholangiocarcinoma.
APA, Harvard, Vancouver, ISO, and other styles
2

Liang, Allison, Sean Munier, and Shabbar Danish. "NIMG-68. MATHEMATICAL MODELING OF THERMAL DAMAGE ESTIMATE VOLUMES IN MAGNETIC RESONANCE-GUIDED LASER INTERSTITIAL THERMAL THERAPY." Neuro-Oncology 22, Supplement_2 (November 2020): ii163. http://dx.doi.org/10.1093/neuonc/noaa215.681.

Full text
Abstract:
Abstract BACKGROUND Magnetic resonance-guided laser interstitial thermal therapy is a minimally invasive procedure that produces real-time thermal damage estimates of ablation (TDE). Orthogonal TDE-MRI slices provides an opportunity to mathematically estimate ablation volume. OBJECTIVE To mathematically model TDE volumes and validate with post-24 hours MRI ablation volumes. METHODS Ablations were performed with the Visualase Laser Ablation System (Medtronic). Using ellipsoidal parameters determined for dual-TDEs from orthogonal MRI planes, TDE volumes were calculated by two definite integral methods (A and B) implemented in Matlab (MathWorks). Post 24-hours MRI ablative volumes were measured in OsiriX (Pixmeo) by two-blinded raters and compared to TDE volumes via paired t-tests and Pearson’s correlations. RESULTS Twenty-two ablations for 20 patients with various intracranial pathologies were included. Average TDE volumes calculated with Method A was 3.44 ± 1.96 cm3 and with Method B was 4.83 ± 1.53 cm3. Method A TDE volumes were significantly different than post-24 hours volumes (P < 0.001). Method B TDE volumes were not significantly different than post-24 hours volumes (P = 0.39) and strongly correlated with each other (r = 0.85, R2 = 0.72, P < 0.0001). A total of 8/22 (36%) method A versus 17/22 (77%) method B TDE volumes were within 25% of the post 24-hours ablative volume. CONCLUSION We present the first iteration of a viable mathematical method that integrates dual-plane TDEs to calculate volumes resembling 24 hours post-operative volumes. Future iterations of our algorithm will need to determine additional calculated variables that improve the performance of volumetric calculations.
APA, Harvard, Vancouver, ISO, and other styles
3

Kim, Sang Hyun, Jae Min Lee, Kang Won Lee, Sang Hoon Kim, Se Hyun Jang, Han Jo Jeon, Seong Ji Choi, et al. "Irreversible electroporation of the bile duct in swine: A pilot study." Journal of Clinical Oncology 38, no. 4_suppl (February 1, 2020): 541. http://dx.doi.org/10.1200/jco.2020.38.4_suppl.541.

Full text
Abstract:
541 Background: Irreversible electroporation (IRE) is a relatively new ablative method. However, the application of IRE ablation has not been attempted for the treatment of biliary disease. Minimally invasive approach using endoscopic retrograde cholangio-pancreatography (ERCP) can be a novel therapeutic modality for IRE ablation. In this study, we investigated the feasibility and effect of endoscopic IRE for biliary tract in animal model. Methods: A new catheter electrode was developed for endoscopic IRE ablation of biliary tract. The electrode for IRE ablation has two band-shaped electrodes on catheter tip. We performed ERCP and endoscopic IRE ablations on normal common bile duct in 6 Yorkshire pigs. Experimental parameters of IRE were 500V/cm, 1000V/cm and 2000V/cm (under 50 pulses, 100 µs length). Animals were sacrificed after 24 hours and ablated bile duct were collected. H & E stain, immunohistochemistry and western blot were performed. Results: Well-demarcated focal color changes were observed on the mucosa of the common bile duct under all experimental parameters. After IRE ablation, bile duct epithelium was disappeared around ablated area and it showed fibrotic change in H&E stain. Depth of change after IRE was different between each experimental parameters. Apoptotic change of bile duct was localized around mucosa in 500V. Diffuse transmural fibrosis of bile duct was shown after IRE ablation with 2000V. TUNEL immunohistochemistry showed the cell death of bile duct mucosa and submucosa along the electrode. Within 24 hours, no complication was observed in pigs after endoscopic IRE ablation. Conclusions: Endoscopic IRE ablation using ERCP was successfully performed on common bile duct by using catheter-shaped electrode. It can be a potential therapeutic option as minimally invasive ablation for treatment of biliary tumors.
APA, Harvard, Vancouver, ISO, and other styles
4

Wimmer, Thomas, Govindarajan Srimathveeravalli, Mikhail Silk, Sebastien Monette, Narendra Gutta, Majid Maybody, Joseph P. Erinjery, Jonathan A. Coleman, Stephen B. Solomon, and Constantinos T. Sofocleous. "Feasibility of a Modified Biopsy Needle for Irreversible Electroporation Ablation and Periprocedural Tissue Sampling." Technology in Cancer Research & Treatment 15, no. 6 (July 9, 2016): 749–58. http://dx.doi.org/10.1177/1533034615608739.

Full text
Abstract:
Objectives: To test the feasibility of modified biopsy needles as probes for irreversible electroporation ablation and periprocedural biopsy. Methods: Core biopsy needles of 16-G/9-cm were customized to serve as experimental ablation probes. Computed tomography-guided percutaneous irreversible electroporation was performed in in vivo porcine kidneys with pairs of experimental (n = 10) or standard probes (n = 10) using a single parameter set (1667 V/cm, ninety 100 µs pulses). Two biopsy samples were taken immediately following ablation using the experimental probes (n = 20). Ablation outcomes were compared using computed tomography, simulation, and histology. Biopsy and necropsy histology were compared. Results: Simulation-suggested ablations with experimental probes were smaller than that with standard electrodes (455.23 vs 543.16 mm2), although both exhibited similar shape. Computed tomography (standard: 556 ± 61 mm2, experimental: 515 ± 67 mm2; P = .25) and histology (standard: 313 ± 77 mm2, experimental: 275 ± 75 mm2; P = .29) indicated ablations with experimental probes were not significantly different from the standard. Histopathology indicated similar morphological changes in both groups. Biopsies from the ablation zone yielded at least 1 core with sufficient tissue for analysis (11 of the 20). Conclusions: A combined probe for irreversible electroporation ablation and periprocedural tissue sampling from the ablation zone is feasible. Ablation outcomes are comparable to those of standard electrodes.
APA, Harvard, Vancouver, ISO, and other styles
5

Steinfort, Daniel P., Michael Christie, Phillip Antippa, Kanishka Rangamuwa, Robert Padera, Michael Rolf Müller, Louis B. Irving, and Arschang Valipour. "Bronchoscopic Thermal Vapour Ablation for Localized Cancer Lesions of the Lung: A Clinical Feasibility Treat-and-Resect Study." Respiration 100, no. 5 (2021): 432–42. http://dx.doi.org/10.1159/000514109.

Full text
Abstract:
<b><i>Background:</i></b> Bronchoscopic thermal vapour ablation (BTVA) is an established and approved modality for minimally invasive lung volume reduction in severe emphysema. Preclinical data suggest potential for BTVA in minimally invasive ablation of lung cancer lesions. <b><i>Objectives:</i></b> The objective of this study is to establish the safety, feasibility, and ablative efficacy of BTVA for minimally invasive ablation of lung cancers. <b><i>Methods:</i></b> Single arm treat-and-resect clinical feasibility study of patients with biopsy-confirmed lung cancer. A novel BTVA for lung cancer (BTVA-C) system for minimally invasive treatment of peripheral pulmonary tumours was used to deliver 330 Cal thermal vapour energy via bronchoscopy to target lesion. Patients underwent planned lobectomy to complete oncologic care. Pre-surgical CT chest and post-resection histologic analysis were performed to evaluate ablative efficacy. <b><i>Results:</i></b> Six patients underwent BTVA-C, and 5 progressed to planned lobectomy. Median procedure duration was 12 min. No major procedure-related complications occurred. All 5 resected lesions were part-solid lung adenocarcinomas with median solid component size 1.32±0.36 cm. Large uniform ablation zones were seen in 4 patients where thermal dose exceeded 3 Cal/mL, with complete/near-complete necrosis of target lesions seen in 2 patients. Tumour positioned within ablation zones demonstrated necrosis in &#x3e;99% of cross-sectional area examined. <b><i>Conclusion:</i></b> BTVA of lung tumours is feasible and well tolerated, with preliminary evidence suggesting high potential for effective ablation of tumours. Thermal injury is well demarcated, and uniform tissue necrosis is observed within ablation zones receiving sufficient thermal dose per volume of lung. Treatment of smaller volumes and ensuring adequate thermal dose may be important for ablative efficacy.
APA, Harvard, Vancouver, ISO, and other styles
6

Hagmeyer, Lars. "Bronchoskopische Thermoablation beim Lungenkarzinom: Ermutigende Daten eines experimentellen Verfahrens." Kompass Pneumologie 9, no. 4 (2021): 189–91. http://dx.doi.org/10.1159/000517810.

Full text
Abstract:
<b>Background:</b> Bronchoscopic thermal vapour ablation (BTVA) is an established and approved modality for minimally invasive lung volume reduction in severe emphysema. Preclinical data suggest potential for BTVA in minimally invasive ablation of lung cancer lesions. <b>Objectives:</b> The objective of this study is to establish the safety, feasibility, and ablative efficacy of BTVA for minimally invasive ablation of lung cancers. <b>Methods:</b> Single arm treat-and-resect clinical feasibility study of patients with biopsy-confirmed lung cancer. A novel BTVA for lung cancer (BTVA-C) system for minimally invasive treatment of peripheral pulmonary tumours was used to deliver 330 Cal thermal vapour energy via bronchoscopy to target lesion. Patients underwent planned lobectomy to complete oncologic care. Pre-surgical CT chest and post-resection histologic analysis were performed to evaluate ablative efficacy. <b>Results:</b> Six patients underwent BTVA-C, and 5 progressed to planned lobectomy. Median procedure duration was 12 min. No major procedure-related complications occurred. All 5 resected lesions were part-solid lung adenocarcinomas with median solid component size 1.32 ± 0.36 cm. Large uniform ablation zones were seen in 4 patients where thermal dose exceeded 3 Cal/mL, with complete/near-complete necrosis of target lesions seen in 2 patients. Tumour positioned within ablation zones demonstrated necrosis in &#x3e;99% of cross-sectional area examined. <b>Conclusion:</b> BTVA of lung tumours is feasible and well tolerated, with preliminary evidence suggesting high potential for effective ablation of tumours. Thermal injury is well demarcated, and uniform tissue necrosis is observed within ablation zones receiving sufficient thermal dose per volume of lung. Treatment of smaller volumes and ensuring adequate thermal dose may be important for ablative efficacy.
APA, Harvard, Vancouver, ISO, and other styles
7

Ito, Toshikazu, Shoji Oura, Naohito Yamamoto, Shinji Nagamine, Masato Takahashi, Hirokazu Tanino, Noboru Yamamichi, et al. "Radiofrequency ablation (RFA) of breast cancer: A multicenter retrospective analysis." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 1119. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.1119.

Full text
Abstract:
1119 Background: Local ablative therapy of breast cancer represents the next frontier in the minimally invasive breast-conservation treatment. We performed a retrospective study of ultrasound-guided percutaneous radiofrequency ablation (RFA) of breast cancers to determine safety and complication related to this treatment. Methods: Four hundred and ninety-seven patients with core biopsy proven breast carcinoma in 10 institutions of non-surgical ablaton study group underwent RFA without surgical excision were enrolled in this study. Results: Mean patient age was 54 years (range 22 - 92 years). Mean tumor size was 1.6 cm. Four hundred and twenty-five tumors ( 86 %) were ≤ 2 cm. The median follow-up period was 50 months (range 3 – 92 months). The mean required for ablation was 19 minutes (range, 4- 72 minutes), and the average temperature of the tumor after ablation was 91 degrees Celsius. The local recurrence rate after RFA was higher in tumors of negative estrogen receptor (8 of 78, 10%) than in tumors of positive estrogen receptor (17 of 437, 4%; p<0.05), and was higher in tumors of positive HER2/neu than in tumors of negative HER2/neu (14.9% vs. 3.2%; p<0.01). The local recurrence rate after RFA was higher in tumors of positive node than in tumors of negative node (9.8% vs. 3.6%), and was higher in tumors without irradiation than in tumors with irradiation (18.2% vs. 3.2%; p<0.001). The local recurrence rate after RFA was higher in tumors of > 2 cm (13 of 72, 18%) than in tumors of ≤ 2 cm (11 of 425, 3%; p<0.001). RFA-relating adverse events were observed in 17 patients of local pain, 14 patients of skin burn and 4 patients of retraction of nipple. Conclusions: RFA is considered to be a safe and promising minimally invasive treatment of small breast cancer ≤ 2 cm in diameter. Further studies are necessary to optimize the technique and evaluate its future role as local therapy for breast cancer.
APA, Harvard, Vancouver, ISO, and other styles
8

Patel, Vipulkumar, Charles A. Ritchie, Carlos Padula, and J. Mark McKinney. "Radiofrequency Ablation, Where It Stands in Interventional Radiology Today." Seminars in Interventional Radiology 36, no. 05 (December 2019): 398–404. http://dx.doi.org/10.1055/s-0039-1697945.

Full text
Abstract:
AbstractRadiofrequency ablation (RFA) is one of the first developed minimally invasive definitive cancer therapies. The safety and efficacy of RFA is well documented and has led to its incorporation into multiple international societal guidelines. By expanding on the body of knowledge acquired during the clinical use of RFA, alternative ablative technologies have emerged and are successfully competing for locoregional therapy market share. The adaption of newer ablative technologies is leading to a rapid decline in the utilization of RFA by interventional radiologists despite the lack of proven superiority. In their 2010 article, Hong and Georgiades stated “… RFA is likely to remain the mainstay of ablations for small tumors until sufficient experience emerges for the widespread acceptance for alternative ablative modalities.” Within a decade of this publication, has this time arrived?
APA, Harvard, Vancouver, ISO, and other styles
9

Tsai, Tsung-Han, Chao Zhou, Hsiang-Chieh Lee, Yuankai K. Tao, Osman O. Ahsen, Marisa Figueiredo, Desmond C. Adler, et al. "Comparison of Tissue Architectural Changes between Radiofrequency Ablation and Cryospray Ablation in Barrett’s Esophagus Using Endoscopic Three-Dimensional Optical Coherence Tomography." Gastroenterology Research and Practice 2012 (2012): 1–8. http://dx.doi.org/10.1155/2012/684832.

Full text
Abstract:
Two main nonsurgical endoscopic approaches for ablating dysplastic and early cancer lesions in the esophagus have gained popularity, namely, radiofrequency ablation (RFA) and cryospray ablation (CSA). We report a uniquely suited endoscopic and near-microscopic imaging modality, three-dimensional (3D) optical coherence tomography (OCT), to assess and compare the esophagus immediately after RFA and CSA. The maximum depths of architectural changes were measured and compared between the two treatment groups. RFA was observed to induce 230~260 μm depth of architectural changes after each set of ablations over a particular region, while CSA was observed to induce edema-like spongiform changes to ~640 μm depth within the ablated field. The ability to obtain micron-scale depth-resolved images of tissue structural changes following different ablation therapies makes 3D-OCT an ideal tool to assess treatment efficacy. Such information could be potentially used to provide real-time feedback for treatment dosing and to identify regions that need further retreatment.
APA, Harvard, Vancouver, ISO, and other styles
10

Camacho, Juan C., Elena N. Petre, and Constantinos T. Sofocleous. "Thermal Ablation of Metastatic Colon Cancer to the Liver." Seminars in Interventional Radiology 36, no. 04 (October 2019): 310–18. http://dx.doi.org/10.1055/s-0039-1698754.

Full text
Abstract:
AbstractColorectal cancer (CRC) is responsible for approximately 10% of cancer-related deaths in the Western world. Liver metastases are frequently seen at the time of diagnosis and throughout the course of the disease. Surgical resection is often considered as it provides long-term survival; however, few patients are candidates for resection. Percutaneous ablative therapies are also used in the management of this patient population. Different thermal ablation (TA) technologies are available including radiofrequency ablation, microwave ablation (MWA), laser, and cryoablation. There is growing evidence about the role of interventional oncology and image-guided percutaneous ablation in the management of metastatic colorectal liver disease. This article aims to outline the technical considerations, outcomes, and rational of TA in the management of patients with CRC liver metastases, focusing on the emerging role of MWA.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cancer ablation"

1

Souteyrand, Philippe. "Ablation radioguidée des masses rénales." Thesis, Aix-Marseille, 2015. http://www.theses.fr/2015AIXM5072/document.

Full text
Abstract:
La prise en charge thérapeutique des tumeurs rénales a considérablement évolué ces dernières années avec l’avènement de traitements mini-invasifs (comme la radiofréquence percutanée) qui optimisent l’épargne néphronique, améliore le confort du patient avec une efficacité oncologique comparable aux traitements chirurgicaux de référence. La prochaine étape serait de proposer des traitements transcutanés aussi performants avec une morbi-mortalité optimisée. L’objectif des travaux réalisés au LIIE du CERIMED (AMU) et au CRCHUM (Université de Montréal) était de développer une alternative à la radiofréquence rénale percutanée que nous utilisons en pratique clinique à Marseille depuis plus de 10 ans et qui a fait ses preuves. Cette alternative doit permettre de traiter des masses rénales avec un niveau d’efficacité et un taux de complications au minimum identique à la RFA, par application transcutanée d’agents physiques sans abord percutané (projet KiTT). Cela passe par la mise au point d’une technique de détection en temps réel de la masse rénale. Nous avons pu développer un algorithme de repérage fiable qui doit encore être optimisé (rapidité de calcul) et être validé sur un modèle qui n’est pas encore disponible. Les travaux d’optimisation et de validation des algorithmes de segmentation, de fonction de mérite de corrélation croisée associée à la fonction d’optimisation Simplex, sont en cours dans le cadre d’une collaboration internationale franco-canadienne au LIIE et au LIO. Même si nous n’avons pas encore la possibilité de proposer ce type de traitement, nos travaux permettent de s’en approcher pour pouvoir les proposer dans les prochaines années
The therapeutic management of renal tumors has changed considerably in recent years with the advent of minimally invasive therapies (such as percutaneous radiofrequency) that maximize nephron savings, improves patient comfort with efficiency comparable to surgical oncology treatments reference. The next step would be to propose transcutaneous treatment (HIFU, stereotactic radiotherapy ...) as efficient with optimized morbidity and mortality.The objective of this work in the context of the LIIE of CERIMED (Aix-Marseille Université) and CRCHUM (Université de Montréal) was to develop an alternative to percutaneous renal radiofrequency we use in clinical practice Marseille for over 10 years and has proved its worth. This alternative must be capable of treating renal masses with a level of effectiveness and complication rates at least equal to the RFA, by applying transcutaneous physical agents without percutaneous approach (project KITT (Kidney Tracking Tumor)). This requires the design of technical point detection in real time of the renal tumor.We were able to develop a reliable identification algorithm that has yet to be optimized (speed of calculation) and be validated on a model that is not yet available. Work optimization and validation of segmentation algorithms, cross correlation merit function associated with Simplex optimization function, are underway as part of an international collaboration to French-Canadian LIIE and LIO.Even if we have not the opportunity to offer this type of treatment, our work allows to approach in order to offer them in the coming years
APA, Harvard, Vancouver, ISO, and other styles
2

Ng, Kwok-chai Kelvin, and 吳國際. "Clinical applications of radiofrequency ablation for hepatocellular carcinoma." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2007. http://hub.hku.hk/bib/B39557674.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

張飛泉 and Fei-chuen Tzang. "Radiofrequency ablation of hepatocellular carcinoma: identifying prognostic factors in long-term survivaloutcome." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2008. http://hub.hku.hk/bib/B40738711.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Manner, Cathyryne Kapiolani. "The consequences of CAT2 arginine transporter ablation in cancer and neuropathology /." Diss., Connect to a 24 p. preview or request complete full text in PDF format. Access restricted to UC campuses, 2003. http://wwwlib.umi.com/cr/ucsd/fullcit?p3091320.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

O'Neill, David Patrick. "Mathematical modelling of the effects of hepatic radiofrequency ablation." Thesis, University of Oxford, 2012. http://ora.ox.ac.uk/objects/uuid:b9ff47fd-0e1a-4ca6-a937-a7e4d49841ba.

Full text
Abstract:
Liver cancer is a major cause of death worldwide and the impact that it has is set to increase in the coming decades. More than half a million cases are diagnosed each year and it is likely many more sufferers are dying unidentified in parts of the world with poor healthcare. Survival rates for untreated cases after diagnosis are low with few patients living beyond one year. A key cause for low survival rates being that the standard treatment is surgical resection; fewer than one quarter of patients are suitable for invasive surgery and five year survival rates rarely exceeds 66 %. RadioFrequency Ablation (RFA) is a minimally invasive technique which utilises the electrically resistive property of tissue to deposit heat energy locally in the vicinity of the tips of an RFA needle. Heat is transferred away through the tissue by conduction, convection of large blood vessels, and bulk flow of blood in smaller vessels. Liver cells, both cancerous and benign, when exposed to the resultant abnormally high temperatures die considerably more rapidly than in cases of natural hyperthermia. It is thus the radiotherapist’s objective to place the RFA needle in a position that maximises destruction of tumour cells, but minimises the collateral damage of surrounding healthy cells. The learning curve of this nontrivial task is reflected unfavourably in the statistics that relate patient survival rate to clinician experience. In this thesis two mathematical models are presented that could be combined into a ‘global’ model of the effects of RFA. To predict cell death in these conditions under RFA, the O’NeillModel is presented in which cells are accounted for by one of three states: alive, vulnerable, and dead. A mechanistic interpretation of the O’Neill Model is attained through comparison to a model from the literature. A known, but little investigated occurrence of tissue swelling in the annular region peripheral to the ablation volume is modelled in a novel way through equations from the literature that track ion transport across the cell membrane; the O’Neill Model for cell death is also incorporated into this model of oedema.
APA, Harvard, Vancouver, ISO, and other styles
6

Hendricks, Alissa Danielle. "Determining the Oncological and Immunological Effects of Histotripsy for Tumor Ablation." Diss., Virginia Tech, 2021. http://hdl.handle.net/10919/103625.

Full text
Abstract:
Histotripsy is an emerging non-invasive, non-thermal, image-guided cancer ablation modality that has recently been approved for its first clinical trial in the United States (NCT04573881). Histotripsy utilizes focused ultrasound to generate acoustic cavitation within a tumor to mechanically fractionate targeted tissues. While pre-clinical work has demonstrated the feasibility of applying histotripsy to solid tumors including primary liver and renal tumors, there is still a need to investigate the potential of histotripsy to treat additional malignancies. In investigating the potential for treating other malignancies there are two avenues that need to be considered: 1) the feasibility for treating tissues with more complex stromal structures and 2) the ability of histotripsy to modulate the tumor microenvironment. To determine the safety and feasibility of additional applications of histotripsy, we conducted dose studies ex vivo on human tumors and human liver to establish dosimetry metrics for applying histotripsy to more fibrotic tumors such as cholangiocarcinoma while sparing nearby critical structures, such as bile ducts and blood vessels. Learning the safety dose-margins from the excised tissues, we performed an in vivo study using mice bearing patient-derived xenograft cholangiocarcinoma tumors. With this model, we were able to demonstrate our ability ablate the stiff cholangiocarcinoma tumors without causing any debilitating off- target damage. To gain a more robust understanding of the effects of histotripsy ablation on potentially difficult to treat tumors, we developed a porcine xenograft tumor model and utilized veterinary cancer patients. These studies have helped established protocols for utilizing histotripsy with ultrasound guidance to treat tumors that are more difficult to treat and can withstand mechanical ablation, including pancreatic adenocarcinoma, osteosarcomas, and soft tissue sarcomas. Pigs share many similarities with human anatomy and physiology, making them an ideal model organism for testing new medical devices and regimes for treating new targets. Using pigs, we were able to establish a procedure to utilize histotripsy to target the pancreas in vivo without causing any lasting or major side effects, such as off-target damage or pancreatitis. One limitation to the porcine model and veterinary patients, is the limitation of gaining rapid insight into the immunological effects of histotripsy. Established cancer mouse models offer the opportunity to rapidly test many organisms with an intact immune system. We used these mice to study pancreatic adenocarcinoma to determine the immune response after histotripsy ablation. For these tumors the general response was an increase in immune cell infiltration post-treatment and a shift in the tumor microenvironment to a more anti-tumor environment. The results of this dissertation provide insight into establishing protocols for treating new types of tumors with histotripsy and immunological effects that lay groundwork for improving future co-therapeutic treatment planning. Future work will aim to translate histotripsy into clinical applications and determining co-therapies that can help control metastasis.
Doctor of Philosophy
Histotripsy is a new medical therapy that can remove tumors without the need for surgery, with the first clinical trial in the United States starting this year, 2021. This therapy uses focused ultrasound waves to generate powerful microscopic bubbles that can rapidly destroy targeted tissues with a high-degree of precision. Early studies on histotripsy have demonstrated the ability of histotripsy to ablate tumors of the liver and kidneys. In order to be able to fully use this therapy on more difficult to target and treat cancers more studies are needed. Given that histotripsy uses physical forces to destroy targets, stronger, more fibrotic tumors and cancers that have begun to spread throughout the body will be more difficult to treat will need more than simple tumor removal to better treat these patients. Therefore, when investigating new cancer applications of histotripsy, it is important to consider the physical features of the tumors as well as the ability of histotripsy to initiate an immune response against the cancer. To determine the safety and feasibility of additional applications of histotripsy, we conducted dose studies on excised human tumors and human liver to see what doses of histotripsy are required to ablate stronger tumors, such as bile duct tumors. Learning the potential safety margins of doses from the excised tissues, we conducted a study using a mouse model to grow stiff, human tumors. With this model, we were able to show that it is possible to ablate the stiffer tumors without causing any major off-target damage. While it is useful to prove in excised tissues and mice that we can treat certain tumors, there is an additional need to study the therapy in a model that is more similar in size and anatomy to humans. Therefore, to gain a better understanding of the effects of histotripsy on potentially difficult to target and ablate tumors, we developed a novel porcine tumor model that can support the growth of human tumors and utilized veterinary cancer patients. These studies have helped established protocols for utilizing histotripsy to treat difficult to physically ablate tumors and difficult to ultrasound target tumors, including pancreatic and bone cancers. Established cancer mouse models offer the opportunity to rapidly test many organisms with an intact immune system. We used these mice to study pancreatic cancer to determine the immune response after histotripsy ablation. For this tumor type, while there were slight differences, the general response was an increase in immune cell infiltration of the tumors post-treatment and a shift to a stronger immune response against the tumor. The results of this dissertation provide insight into establishing protocols for treating new types of tumors with histotripsy and immune effects that lay groundwork for improving future co-therapeutic planning. Future work will aim to translate histotripsy into clinical applications and determining co-therapies that can help control body-wide disease.
APA, Harvard, Vancouver, ISO, and other styles
7

Ng, Kwok-chai Kelvin, and 吳國際. "Local and systemic effects of hepatic radiofrequency ablation in animal models." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2004. http://hub.hku.hk/bib/B29434920.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Klossner, Daniel Patrick. "Improving cryosurgical ablation of advanced state prostate cancer through identification of molecular targets in a prostrate cancer cell model." Diss., Online access via UMI:, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Mukherjee, Souvick. "Multiple antenna microwave ablation: impact of non-parallel antenna insertion." Thesis, Kansas State University, 2015. http://hdl.handle.net/2097/19058.

Full text
Abstract:
Master of Science
Department of Electrical and Computer Engineering
Punit Prakash
Microwave ablation is a minimally invasive therapeutic modality used for the treatment of cancer in various organs. In this procedure, microwave energy is sent through a thin antenna placed inside the tumor. The microwave energy radiated from the antenna generates heat which kills the tumor cells by necrosis. During multiple-applicator microwave ablation, geometric estimates of treatment outcome are typically obtained by assuming parallel insertion of the applicators. This assumption is based on the guidelines provided in the brochures of antenna manufacturing companies. This assumption is flawed because it is rare to insert the antennas in parallel configuration due to the flexible nature of the antennas and the presence of intervening organs. Furthermore, movement of patients during the treatment procedure alters the position of the antennas. In order to see the effect of non-parallel insertion of antennas, model-based treatment planning may be instructive. Treatment planning can also determine the changes needed to be made for prospective ablation therapy if the antennas are not positioned in their ideal parallel configuration. This thesis provides a detailed computational comparison of the skewed configurations of microwave antennas to their closest parallel configurations. The metric used for com-paring the similarity between the cases is Dice Similarity Coefficient (DSC). Experimental results to validate the computational data are also discussed. Computations were done by using realistic cases of antenna positions obtained from Rhode Island Hospital.
APA, Harvard, Vancouver, ISO, and other styles
10

Adams, Jacob James. "A coupled electromagnetic-thermal model of heating during radiofrequency ablation." Connect to resource, 2007. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1191454972.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Cancer ablation"

1

Percutaneous tumor ablation: Strategies and techniques. New York: Thieme, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kinoshita, Takayuki, ed. Non-surgical Ablation Therapy for Early-stage Breast Cancer. Tokyo: Springer Japan, 2016. http://dx.doi.org/10.1007/978-4-431-54463-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hong, Kelvin. Percutaneous tumor ablation: Strategies and techniques. New York: Thieme, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Radiofrequency Ablation for Cancer. New York: Springer-Verlag, 2004. http://dx.doi.org/10.1007/b97314.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Tumor Ablation Tumor Microenvironment. Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Faddegon, Stephen, Ephrem O. Olweny, and Jeffrey A. Cadeddu. Ablative technologies for renal cancer. Edited by James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0087.

Full text
Abstract:
Nearly two-thirds of newly detected renal masses are clinical stage 1, with T1a tumours accounting for 60% of the newly detected stage 1 tumours. Guideline panels convened by the American Urological Association and the European Association of Urology recommend nephron-sparing surgery as the gold standard treatment for small renal masses, with active surveillance and thermal ablation recommended as alternative strategies in select patients. However, there is a dearth of studies directly comparing outcomes for energy-based ablation to those for traditional surgical treatments for small renal masses, and future prospective randomized trials will be invaluable in this regard. Ongoing research in renal tumour ablation targets several areas, including but not limited to achieving larger ablation sizes, decreasing morbidity, and development of novel technologies for renal tumour ablation.
APA, Harvard, Vancouver, ISO, and other styles
7

M, Ellis Lee, Curley Steven A, and Tanabe Kenneth K, eds. Radiofrequency ablation for cancer: Current indications, techniques, and outcomes. New York: Springer, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Radiofrequency ablation for cancer: Current indication, techniques, and outcomes. New York, NY: Springer, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

(Adapter), T. Livraghi, P. Mueller (Adapter), S. Silverman (Adapter), Eric vanSonnenberg (Editor), William McMullen (Editor), and Luigi Solbiati (Editor), eds. Tumor Ablation: Principles and Practice. Springer, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

(Editor), Lee M. Ellis, Steven A. Curley (Editor), and Kenneth K. Tanabe (Editor), eds. Radiofrequency Ablation for Cancer: Current Indications, Techniques and Outcomes. Springer, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Cancer ablation"

1

Yarmohammadi, Hooman. "Ablative Techniques for Painful Metastasis (Radiofrequency ablation, Microwave ablation, Cryoablation, Chemical ablation, and HIFU)." In Essentials of Interventional Cancer Pain Management, 307–17. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-99684-4_35.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Schwab, Manfred. "Androgen Ablation Therapy." In Encyclopedia of Cancer, 1. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-27841-9_6775-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Robinson, David S. "In Situ Laser Ablation." In Breast Cancer, 321–31. New York, NY: Springer New York, 1999. http://dx.doi.org/10.1007/978-1-4612-2146-3_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

McKay, Andrew, Elijah Dixon, and Oliver Bathe. "Colorectal Liver Metastases: Radiofrequency Ablation." In Colorectal Cancer, 445–60. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-1-4020-9545-0_27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Van Nostrand, Douglas. "Prescribed Activity for Radioiodine Ablation." In Thyroid Cancer, 273–82. Totowa, NJ: Humana Press, 2006. http://dx.doi.org/10.1007/978-1-59259-995-0_26.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Boll, Daniel T., Jonathan S. Lewin, Sherif G. Nour, and Elmar M. Merkle. "Magnetic Resonance Imaging Guidance of Radiofrequency Thermal Ablation for Cancer Treatment." In Tumor Ablation, 167–81. New York, NY: Springer New York, 2005. http://dx.doi.org/10.1007/0-387-28674-8_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Johnson, Bruce E., and Pasi A. Jänne. "Tumor Ablation for Patients with Lung Cancer: The Thoracic Oncologist’s Perspective." In Tumor Ablation, 459–65. New York, NY: Springer New York, 2005. http://dx.doi.org/10.1007/0-387-28674-8_38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nierkens, Stefan, Martijn H. den Brok, Theo J. Ruers, and Gosse J. Adema. "Radiofrequency Ablation in Cancer Therapy: Tuning in to in situ Tumor Vaccines." In Tumor Ablation, 39–59. Dordrecht: Springer Netherlands, 2012. http://dx.doi.org/10.1007/978-94-007-4694-7_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Khoury-Collado, Fady, and Yukio Sonoda. "Ablation of Gynecologic Cancers." In Image-Guided Cancer Therapy, 843–55. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4419-0751-6_59.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pacini, Furio, and Maria Grazia Castagna. "Radioiodine Ablation: Current Status." In Practical Management of Thyroid Cancer, 131–35. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-91725-2_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cancer ablation"

1

Tse, Zion Tsz Ho, Sheng Xu, Alexander Squires, Yue Chen, Reza Seifabadi, Harsh Agrawal, Peter Pinto, Peter Choyke, and Bradford Wood. "Robot for MRI-Guided Prostate Cancer Focal Laser Ablation." In 2017 Design of Medical Devices Conference. American Society of Mechanical Engineers, 2017. http://dx.doi.org/10.1115/dmd2017-3511.

Full text
Abstract:
Prostate cancer is the most common cancer among males, leading to approximately 27,000 deaths in the United States [1]. Focal laser ablation (FLA) has been shown to be a promising approach for prostate cancer treatment with the advantage of efficiently ablating the cancer cells while inflicting less damage on the surrounding tissues. In current FLA procedures, a rigid template — with holes spacing of 5mm — guides the FLA catheter to the target position. Drawbacks of the conventional approach for catheter targeting are 1) limited degrees of freedom (DoF) and 2) a low insertion resolution. In addition, the targeting capability of the rigid template is compromised when the pubic arch or nerve bundles intersect the catheter trajectory. We hypothesized that a compact design of an MRI-conditional robot with two active planar DoFs, one passive rotation DoF, and remote catheter insertion capacities could enhance the clinical workflow required for MRI-guided FLA prostate procedures.
APA, Harvard, Vancouver, ISO, and other styles
2

Tzoracoleftherakis, E., E. Sdralis, J. Maroulis, and P. Ravazoula. "Radiofrequency Ablation in Breast Cancer." In Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-2106.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hanks, Bradley W., Mary Frecker, and Matthew Moyer. "Design of a Compliant Endoscopic Ultrasound-Guided Radiofrequency Ablation Probe." In ASME 2016 International Design Engineering Technical Conferences and Computers and Information in Engineering Conference. American Society of Mechanical Engineers, 2016. http://dx.doi.org/10.1115/detc2016-59923.

Full text
Abstract:
Pancreatic cancer is one of the most deadly forms of cancer in the United States. Due to its late diagnosis, only 20% of patients diagnosed with the disease are eligible for surgical resection which is considered the preferred method of treatment. Radiofrequency ablation is a common cancer treatment modality for patients ineligible for open surgery. There is a lack of ablation probes which may be used to generate spherical heating zones which closely match the geometry of typical tumors. In particular, there are no endoscopic ablation probes commercially available in the United States. In this paper the design of a compliant endoscopic radiofrequency ablation probe is presented. This probe features an array of compliant tines which deploy through the cancerous tissue to effectively broaden the ablation zone. A thermal ablation model is used to inform the design of the geometry of the probe. In addition, finite element analysis is used to determine the feasibility of the compliant structures. These design tools are used as aids to inform the design and direct modifications toward a feasible probe which generates a spherical ablation zone.
APA, Harvard, Vancouver, ISO, and other styles
4

Kanazawa, K., and S. Kidera. "Waveform Matching Based Real-time Ablation Monitoring for Microwave Breast Cancer Ablation." In 12th European Conference on Antennas and Propagation (EuCAP 2018). Institution of Engineering and Technology, 2018. http://dx.doi.org/10.1049/cp.2018.0490.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Primak, Svetlana V., Yuan Le, Kevin J. Glaser, Carol A. Reynold, Jinping Lai, Lewis R. Roberts, Philip J. Rossman, Joel P. Felmlee, and Richard L. Ehman. "Magnetic Resonance Elastography Assessment of Focused Ultrasound Surgery in Cancer Models: A Pilot Study." In ASME 2006 International Mechanical Engineering Congress and Exposition. ASMEDC, 2006. http://dx.doi.org/10.1115/imece2006-16010.

Full text
Abstract:
MRI guided focused ultrasound (FUS) has been shown to create thermal lesions where tissue stiffness changes significantly. To assess the correlation between tissue stiffness change and tissue ablation, a pilot animal based study was conducted to treat LNCaP tumors in vivo and Hep3B tumors immediately post mortem. MR elastography was used to analyze tissue stiffness before and after ablation. Treated tissue was excised immediately after each experiment and processed by routine histological analysis. Four prostate cancer tumors and four liver cancer tumors showed, on average, a threefold increase in stiffness due to FUS thermal treatment. Histology showed complete (100%) coagulation necrosis in these cases. These data suggest that MRE may be an effective means to assess tissue ablation.
APA, Harvard, Vancouver, ISO, and other styles
6

Noguchi, M., M. Earashi, and A. Motoyoshi. "Radiofrequency ablation treatment for small breast cancer." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-5155.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mourad, Mouhamad, Mohammed Ajam, and Mohammad Ayache. "Liver Tumor Ablation Enhancement by Lean Concept." In 2018 1st International Conference on Cancer Care Informatics (CCI). IEEE, 2018. http://dx.doi.org/10.1109/cancercare.2018.8618254.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Gamez, E. S., A. Rajagopalan, D. Y. Furgeson, and G. Lazzi. "Antenna design for microwave cancer ablation of osteosarcoma." In 2013 US National Committee of URSI National Radio Science Meeting (USNC-URSI NRSM). IEEE, 2013. http://dx.doi.org/10.1109/usnc-ursi-nrsm.2013.6525128.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Harms, Steven E., Hamid Mumtaz, Brian Hyslop, Suzanne Klimberg, Kent Westbrook, and Sohelia Kourourian. "RODEO MRI guided laser ablation of breast cancer." In BiOS '99 International Biomedical Optics Symposium, edited by R. Rox Anderson, Kenneth E. Bartels, Lawrence S. Bass, Darryl J. Bornhop, C. Gaelyn Garrett, Kenton W. Gregory, Nikiforos Kollias, et al. SPIE, 1999. http://dx.doi.org/10.1117/12.351004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Spiliotis, A., G. Gäbelein, S. Holländer, PR Scherber, B. Patel, and M. Glanemann. "Radiofrequency ablation compared with microwave ablation for the treatment of liver cancer: a meta-analysis." In 37. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber. Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0040-1722058.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Cancer ablation"

1

Jhiang, Sissy M. Sodium Iodide Symporter Gene Transfer for Imaging and Ablation of Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, January 2003. http://dx.doi.org/10.21236/ada414854.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Tepper, Clifford G. Molecular Targeting of Prostate Cancer during Androgen Ablation: Inhibition of CHES1/FOXN3. Fort Belvoir, VA: Defense Technical Information Center, May 2012. http://dx.doi.org/10.21236/ada587673.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tepper, Clifford G., and Tamlyn Tsubota. Molecular Targeting of Prostate Cancer During Androgen Ablation: Inhibition of CHES1/FOXN3. Fort Belvoir, VA: Defense Technical Information Center, May 2013. http://dx.doi.org/10.21236/ada599249.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jhiang, Sissy M. Sodium Iodide Symporter Gene Transfer for Imaging and Ablation of Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, January 2005. http://dx.doi.org/10.21236/ada439214.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Jhiang, Sissy M. Sodium Iodide Symporter Gene Transfer for Imaging and Ablation of Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, January 2004. http://dx.doi.org/10.21236/ada423266.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Tepper, Clifford. Molecular Targeting of Prostate Cancer During Androgen Ablation: Inhibition of CHES1/FOXN3. Fort Belvoir, VA: Defense Technical Information Center, May 2011. http://dx.doi.org/10.21236/ada547340.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

El-Sayed, Mohamed E. Development of Targeted Nanobubbles for Ultrasound Imaging and Ablation of Metastatic Prostate Cancer Lesions. Fort Belvoir, VA: Defense Technical Information Center, August 2014. http://dx.doi.org/10.21236/ada613959.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

El-Sayed, Mohamed. Development of Targeted Nanobubbles for Ultrasound Imaging and Ablation of Metastatic Prostate Cancer Lesions. Fort Belvoir, VA: Defense Technical Information Center, August 2013. http://dx.doi.org/10.21236/ada594876.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Yuan, Fang. A Novel Combination of Thermal Ablation and Heat-Inducible Gene therapy for Breast Cancer Treatment. Fort Belvoir, VA: Defense Technical Information Center, April 2009. http://dx.doi.org/10.21236/ada540198.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kwon, Eugene D. Androgen Ablation Combined With CTLA-4 Blockade-Based Immunotherapy as a Treatment for Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, January 2003. http://dx.doi.org/10.21236/ada416705.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cancer ablation' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography